Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 2 | 2019 | 111 | 1.280 |
Why?
|
| Analgesia, Obstetrical | 3 | 2018 | 15 | 1.240 |
Why?
|
| Analgesia, Epidural | 3 | 2018 | 40 | 1.210 |
Why?
|
| Myocardial Contraction | 19 | 1998 | 383 | 0.800 |
Why?
|
| Anesthesia, Obstetrical | 3 | 2015 | 11 | 0.750 |
Why?
|
| Cesarean Section | 2 | 2019 | 101 | 0.750 |
Why?
|
| Anesthesiologists | 1 | 2021 | 30 | 0.740 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 60 | 0.730 |
Why?
|
| Breakthrough Pain | 1 | 2019 | 3 | 0.690 |
Why?
|
| Pregnancy | 11 | 2019 | 2334 | 0.670 |
Why?
|
| Analgesia | 1 | 2019 | 58 | 0.660 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2019 | 45 | 0.650 |
Why?
|
| Intensive Care Units | 2 | 2021 | 344 | 0.620 |
Why?
|
| Labor, Obstetric | 1 | 2018 | 23 | 0.610 |
Why?
|
| Needles | 1 | 2018 | 34 | 0.610 |
Why?
|
| Bupivacaine | 1 | 2018 | 27 | 0.600 |
Why?
|
| Liver Transplantation | 1 | 2021 | 400 | 0.600 |
Why?
|
| Anesthetics, Local | 1 | 2018 | 83 | 0.580 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 214 | 0.580 |
Why?
|
| Length of Stay | 2 | 2021 | 780 | 0.570 |
Why?
|
| Heart Arrest, Induced | 9 | 1998 | 52 | 0.550 |
Why?
|
| Apgar Score | 1 | 2016 | 22 | 0.540 |
Why?
|
| Postpartum Hemorrhage | 1 | 2015 | 12 | 0.510 |
Why?
|
| Hospital Costs | 1 | 2016 | 117 | 0.510 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 498 | 0.460 |
Why?
|
| Airway Management | 1 | 2013 | 20 | 0.450 |
Why?
|
| Patient Readmission | 1 | 2016 | 267 | 0.450 |
Why?
|
| Intubation, Intratracheal | 1 | 2013 | 99 | 0.430 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 365 | 0.430 |
Why?
|
| Pregnancy Complications | 3 | 2012 | 286 | 0.420 |
Why?
|
| Anesthetics, Intravenous | 3 | 2012 | 27 | 0.380 |
Why?
|
| Propofol | 3 | 2012 | 36 | 0.380 |
Why?
|
| Heart Failure | 13 | 1999 | 1180 | 0.370 |
Why?
|
| Anesthesia, Epidural | 1 | 2009 | 11 | 0.340 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 89 | 0.340 |
Why?
|
| Tachycardia | 2 | 2007 | 53 | 0.320 |
Why?
|
| Device Removal | 1 | 2009 | 100 | 0.310 |
Why?
|
| Catheterization | 1 | 2009 | 209 | 0.310 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 839 | 0.310 |
Why?
|
| Posture | 2 | 2012 | 107 | 0.300 |
Why?
|
| Pain Measurement | 2 | 2019 | 328 | 0.300 |
Why?
|
| Obesity, Morbid | 1 | 2009 | 172 | 0.280 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2007 | 34 | 0.280 |
Why?
|
| Potassium Channels | 5 | 1998 | 55 | 0.270 |
Why?
|
| Swine | 21 | 1999 | 672 | 0.270 |
Why?
|
| Ventricular Function, Left | 12 | 1999 | 481 | 0.270 |
Why?
|
| Female | 14 | 2021 | 38074 | 0.250 |
Why?
|
| Myocardium | 12 | 1998 | 1204 | 0.250 |
Why?
|
| Picolines | 4 | 1998 | 8 | 0.240 |
Why?
|
| Pyrans | 4 | 1998 | 16 | 0.240 |
Why?
|
| Fever | 2 | 2018 | 96 | 0.240 |
Why?
|
| Humans | 16 | 2021 | 68618 | 0.230 |
Why?
|
| Ventilators, Mechanical | 1 | 2021 | 13 | 0.190 |
Why?
|
| Heart | 6 | 1998 | 850 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2016 | 2358 | 0.190 |
Why?
|
| Adult | 7 | 2019 | 21403 | 0.190 |
Why?
|
| Cardiotonic Agents | 2 | 1998 | 71 | 0.190 |
Why?
|
| Erythrocyte Transfusion | 1 | 2021 | 72 | 0.190 |
Why?
|
| Adenosine Triphosphate | 3 | 1998 | 314 | 0.180 |
Why?
|
| Thrombocytopenia | 2 | 2015 | 122 | 0.180 |
Why?
|
| Hypothermia, Induced | 3 | 1998 | 93 | 0.180 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2018 | 91 | 0.170 |
Why?
|
| Ketorolac | 1 | 2019 | 11 | 0.170 |
Why?
|
| Anesthesia, Spinal | 1 | 2019 | 16 | 0.170 |
Why?
|
| Metalloendopeptidases | 2 | 1998 | 67 | 0.160 |
Why?
|
| Odds Ratio | 1 | 2021 | 880 | 0.160 |
Why?
|
| Time Factors | 9 | 2018 | 4655 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2019 | 411 | 0.160 |
Why?
|
| Methylprednisolone | 1 | 2018 | 99 | 0.150 |
Why?
|
| Injections, Spinal | 1 | 2018 | 18 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2021 | 7277 | 0.150 |
Why?
|
| Graft Rejection | 1 | 2021 | 458 | 0.150 |
Why?
|
| Pain Management | 1 | 2019 | 186 | 0.150 |
Why?
|
| Isoproterenol | 7 | 1998 | 163 | 0.150 |
Why?
|
| Hypertension | 1 | 2007 | 1535 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 240 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2018 | 330 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2018 | 222 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 1 | 1997 | 96 | 0.140 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2015 | 15 | 0.130 |
Why?
|
| Cardiac Pacing, Artificial | 6 | 1998 | 174 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 1998 | 277 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2016 | 238 | 0.130 |
Why?
|
| Adrenergic beta-Agonists | 5 | 1998 | 92 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2016 | 163 | 0.130 |
Why?
|
| Collagen | 1 | 1998 | 636 | 0.120 |
Why?
|
| Valine | 3 | 1998 | 43 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2016 | 652 | 0.110 |
Why?
|
| Cardioplegic Solutions | 3 | 1998 | 15 | 0.110 |
Why?
|
| Vasodilator Agents | 3 | 1999 | 138 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2014 | 737 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2016 | 346 | 0.110 |
Why?
|
| Tetrazoles | 3 | 1998 | 160 | 0.110 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 1998 | 155 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 1998 | 202 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1054 | 0.110 |
Why?
|
| Pterygium | 1 | 2012 | 3 | 0.100 |
Why?
|
| Inflammation | 1 | 2018 | 1030 | 0.100 |
Why?
|
| Malignant Hyperthermia | 1 | 2012 | 10 | 0.100 |
Why?
|
| Cells, Cultured | 7 | 1998 | 2673 | 0.100 |
Why?
|
| Young Adult | 3 | 2019 | 5717 | 0.100 |
Why?
|
| Anesthesia, General | 1 | 2012 | 86 | 0.100 |
Why?
|
| Middle Aged | 3 | 2021 | 21147 | 0.100 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 109 | 0.100 |
Why?
|
| Animals | 22 | 1999 | 20881 | 0.090 |
Why?
|
| Male | 6 | 2021 | 37321 | 0.090 |
Why?
|
| Hemodynamics | 5 | 1999 | 705 | 0.090 |
Why?
|
| Obstetric Labor Complications | 1 | 2010 | 20 | 0.090 |
Why?
|
| Chorioamnionitis | 1 | 2010 | 40 | 0.090 |
Why?
|
| Endothelins | 3 | 1999 | 57 | 0.090 |
Why?
|
| Microscopy, Video | 3 | 1998 | 27 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2021 | 7029 | 0.080 |
Why?
|
| Amlodipine | 2 | 1999 | 31 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta | 3 | 1998 | 153 | 0.080 |
Why?
|
| Potassium | 3 | 1998 | 168 | 0.080 |
Why?
|
| Adolescent | 2 | 2014 | 8912 | 0.080 |
Why?
|
| Rewarming | 2 | 1998 | 11 | 0.070 |
Why?
|
| Isotonic Solutions | 2 | 1998 | 25 | 0.070 |
Why?
|
| Renin-Angiotensin System | 2 | 1997 | 79 | 0.070 |
Why?
|
| Benzazepines | 2 | 1997 | 104 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2014 | 3705 | 0.070 |
Why?
|
| Disease Models, Animal | 6 | 1999 | 2550 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2010 | 718 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 1996 | 189 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 219 | 0.060 |
Why?
|
| Pipecolic Acids | 1 | 2005 | 9 | 0.060 |
Why?
|
| Heart Ventricles | 3 | 1998 | 738 | 0.060 |
Why?
|
| Endarterectomy, Carotid | 1 | 2005 | 110 | 0.060 |
Why?
|
| Heparin | 1 | 2005 | 205 | 0.060 |
Why?
|
| Exercise Test | 3 | 1999 | 242 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1998 | 689 | 0.060 |
Why?
|
| Myocardial Reperfusion | 3 | 1998 | 32 | 0.060 |
Why?
|
| Child | 1 | 2014 | 6405 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2007 | 1451 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2005 | 356 | 0.050 |
Why?
|
| Renin | 2 | 1999 | 96 | 0.050 |
Why?
|
| Epinephrine | 2 | 1999 | 103 | 0.050 |
Why?
|
| Aged | 2 | 2016 | 14862 | 0.050 |
Why?
|
| Antihypertensive Agents | 3 | 1998 | 498 | 0.040 |
Why?
|
| Cardiovascular Agents | 2 | 1998 | 82 | 0.040 |
Why?
|
| Random Allocation | 2 | 1998 | 442 | 0.040 |
Why?
|
| Adenosine | 2 | 1997 | 165 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2018 | 2455 | 0.040 |
Why?
|
| Thiazepines | 1 | 1998 | 14 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1998 | 38 | 0.040 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 1998 | 17 | 0.040 |
Why?
|
| Neprilysin | 1 | 1998 | 55 | 0.040 |
Why?
|
| Ventricular Function | 1 | 1998 | 93 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2018 | 131 | 0.040 |
Why?
|
| Glyburide | 1 | 1998 | 19 | 0.040 |
Why?
|
| Potassium Channel Blockers | 1 | 1998 | 32 | 0.040 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 1997 | 16 | 0.040 |
Why?
|
| Angiotensin II | 1 | 1998 | 220 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 1998 | 218 | 0.040 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 1996 | 7 | 0.040 |
Why?
|
| Atenolol | 1 | 1996 | 20 | 0.040 |
Why?
|
| Plasma Substitutes | 1 | 1996 | 15 | 0.040 |
Why?
|
| Pyridines | 1 | 1998 | 261 | 0.040 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1996 | 73 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1997 | 1745 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 100 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 659 | 0.030 |
Why?
|
| Heart Rate | 1 | 1997 | 568 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1738 | 0.030 |
Why?
|
| Valsartan | 3 | 1998 | 99 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 1753 | 0.030 |
Why?
|
| Intubation | 1 | 2012 | 20 | 0.030 |
Why?
|
| Isoflurane | 1 | 2012 | 16 | 0.030 |
Why?
|
| Anesthetics, Inhalation | 1 | 2012 | 21 | 0.030 |
Why?
|
| Skin Abnormalities | 1 | 2012 | 11 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 2012 | 40 | 0.030 |
Why?
|
| Midazolam | 1 | 2012 | 46 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2012 | 61 | 0.020 |
Why?
|
| Ketamine | 1 | 2012 | 57 | 0.020 |
Why?
|
| Analgesics | 1 | 2012 | 118 | 0.020 |
Why?
|
| Labor Stage, First | 1 | 2010 | 5 | 0.020 |
Why?
|
| Seizures, Febrile | 1 | 2010 | 10 | 0.020 |
Why?
|
| Calcium | 3 | 1998 | 929 | 0.020 |
Why?
|
| Regional Blood Flow | 2 | 1999 | 168 | 0.020 |
Why?
|
| Hormones | 2 | 1998 | 42 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5731 | 0.020 |
Why?
|
| Vascular Resistance | 2 | 1999 | 179 | 0.020 |
Why?
|
| Signal Transduction | 1 | 1998 | 2689 | 0.020 |
Why?
|
| Coronary Circulation | 2 | 1999 | 136 | 0.020 |
Why?
|
| Cell Separation | 2 | 1998 | 132 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 1997 | 31 | 0.020 |
Why?
|
| Receptors, Angiotensin | 2 | 1997 | 59 | 0.020 |
Why?
|
| Calcium Channels | 2 | 1998 | 59 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 1997 | 80 | 0.020 |
Why?
|
| Sepsis | 1 | 2010 | 233 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2010 | 1553 | 0.020 |
Why?
|
| Kinetics | 2 | 1997 | 1047 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2005 | 31 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 1997 | 1040 | 0.020 |
Why?
|
| Arginine | 1 | 2005 | 102 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2005 | 141 | 0.010 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2005 | 139 | 0.010 |
Why?
|
| Renal Circulation | 1 | 1999 | 49 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 1999 | 79 | 0.010 |
Why?
|
| Chromans | 1 | 1998 | 12 | 0.010 |
Why?
|
| Receptor, Endothelin A | 1 | 1998 | 35 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1998 | 102 | 0.010 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1998 | 10 | 0.010 |
Why?
|
| Colforsin | 1 | 1998 | 42 | 0.010 |
Why?
|
| Calcium Channel Agonists | 1 | 1998 | 18 | 0.010 |
Why?
|
| Adenylyl Cyclases | 1 | 1998 | 94 | 0.010 |
Why?
|
| Dihydropyridines | 1 | 1997 | 13 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 490 | 0.010 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1997 | 40 | 0.010 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1997 | 40 | 0.010 |
Why?
|
| Aldosterone | 1 | 1997 | 51 | 0.010 |
Why?
|
| Calcium Channels, L-Type | 1 | 1997 | 34 | 0.010 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1997 | 72 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1997 | 133 | 0.010 |
Why?
|
| Mathematics | 1 | 1997 | 83 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 1997 | 114 | 0.010 |
Why?
|
| Diastole | 1 | 1997 | 161 | 0.010 |
Why?
|
| Sarcolemma | 1 | 1996 | 16 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1997 | 152 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1997 | 276 | 0.010 |
Why?
|
| Receptors, Endothelin | 1 | 1996 | 30 | 0.010 |
Why?
|
| Catecholamines | 1 | 1996 | 73 | 0.010 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 1997 | 84 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1999 | 586 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 1997 | 133 | 0.010 |
Why?
|
| Biopsy | 1 | 1998 | 540 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 1998 | 313 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1997 | 525 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 1996 | 189 | 0.010 |
Why?
|
| Reference Values | 1 | 1996 | 579 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1997 | 323 | 0.010 |
Why?
|
| Disease Progression | 1 | 1998 | 1038 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 1996 | 189 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 1996 | 172 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1997 | 1330 | 0.010 |
Why?
|